Published in TB and Outbreaks Week, September 10th, 2002
The immune response modifier called resiquimod is a topical treatment that is more potent than a similar drug used for treating human papillomavirus infections, said Dr. Daron G. Ferris, family medicine physician and investigator.
"We are very excited about this agent's potential because it represents a new class of drugs that has not been previously available for treating genital herpes," he said. Antiviral drugs currently used to treat genital herpes don't eliminate the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.